While the mechanism of AXL overexpression upon acquired resistance remains unclear in vivo, one study suggests that hypomethylation of the AXL promoter may play a role in AXL overexpression in ErbB2-positive breast cancer cells upon acquisition of resistance to the ErbB2 inhibitor, lapatinib. This evidence concerns the gene ERBB2 and breast carcinoma.